GlycoNex Inc. was founded in 2001. It GlycoNex has grown to be the pioneer in Taiwan that combines glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs. Marching into 2012, GlycoNex has possessed advanced and complete technology platform:glycosphingolipid antigen production and identification,monoclonal antibody production, cancer drug screening, stable cell line production for monoclonal antibody, pharmacology/pharmacokinetics assessment.
Headquarters
8F., No.97, Sec. 1, Xintai 5Th Rd., Xizhi Dist
New Taipei City; New Taipei City;
Contact Details: Purchase the Glyconex Incorporation (台湾醣联生技医药股份有限公司) report to view the information.
Website: http://www.glyconex.com.tw
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service